세계의 발기부전 치료 시장 규모, 점유율, 성장 분석, 유형별, 투여 경로별, 지역별 시장 규모, 점유율, 성장 분석 - 산업 예측(2024-2031년)

Global Erectile Dysfunction Drugs Market size was valued at USD 2.4 billion in 2022 and is poised to grow from USD 2.62 billion in 2023 to USD 5.3 billion by 2031, growing at a CAGR of 9.20% during the forecast period (2024-2031).

The global market for erectile dysfunction drugs is witnessing significant growth driven by several interconnected factors. The rise in sedentary lifestyles, alongside the prevalence of lifestyle-related conditions such as obesity, cardiovascular diseases, diabetes, and hypertension, is leading to a higher demand for these medications. Additionally, the growing geriatric population is amplifying the need for effective treatment options, supported by increased patient awareness around erectile dysfunction. Government initiatives and public health campaigns in developing regions are further propelling market expansion. The presence of generic drug alternatives and associated lifestyle stresses are enhancing market dynamics as well. Furthermore, an increasing number of men experiencing erectile dysfunction, coupled with the expiration of patents for major drugs, is proving advantageous for the market landscape. Investment in research and development, along with clinical trials focusing on innovative treatments, is creating robust growth opportunities. However, the market faces challenges such as poor patient adherence, the prevalence of counterfeit medications, and potential adverse effects that may impede progress. As the market evolves, addressing these hurdles while capitalizing on growth drivers will be crucial for stakeholders to navigate the complexities of the erectile dysfunction drug market effectively.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Erectile Dysfunction Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Erectile Dysfunction Drugs Market Segmental Analysis

Global Erectile Dysfunction Drugs Market is segmented by Type, Route of Administration, and region. Based on Type, the market is segmented into Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), and Other Drugs. Based on Route of Administration, the market is segmented into Oral Mode of Administration, Injectable Mode of Administration, and Other Modes of Administration. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Erectile Dysfunction Drugs Market

The escalating prevalence of erectile dysfunction (ED) worldwide significantly propels the Global Erectile Dysfunction Drugs market, driven by a confluence of factors including sedentary lifestyles, obesity, and age-related changes. Chronic health conditions such as diabetes and cardiovascular diseases further exacerbate this issue, leading to a higher demand for effective treatment options. As societal awareness surrounding men's health increases and stigma surrounding ED diminishes, more individuals are seeking medical interventions. This trend is further supported by ongoing innovations in pharmaceutical therapies, bolstering the market's growth as a rising number of patients turn to prescribed medications and over-the-counter solutions to enhance their sexual health and overall quality of life.

Restraints in the Global Erectile Dysfunction Drugs Market

One significant market restraint for the global erectile dysfunction drugs market is the rigorous regulatory landscape governing drug development and approval. The process involves extensive clinical trials and stringent post-marketing surveillance requirements, which are both time-consuming and costly for manufacturers. These regulatory hurdles can delay product launches and increase the overall investment needed for bringing new drugs to market. Consequently, the complexity and duration of the approval process may deter potential entrants and limit innovation within the sector, ultimately constraining market growth and reducing the availability of novel treatment options for consumers seeking effective erectile dysfunction solutions.

Market Trends of the Global Erectile Dysfunction Drugs Market

The Global Erectile Dysfunction Drugs market is experiencing a notable shift towards non-oral administration routes, driven by an evolving consumer preference for treatment options that enhance convenience and immediacy. As traditional oral medications, particularly PDE5 inhibitors, continue to dominate the landscape, there is a marked rise in interest for alternative methods such as topical creams, injections, and transdermal patches. These innovative delivery systems provide localized treatment, potentially reducing systemic side effects and improving efficacy. This trend reflects a broader movement towards personalized medicine, catering to diverse patient needs and preferences, thereby fostering growth opportunities within the market.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Ecosystem of the Market
• Case study Analysis
• PESTEL Analysis
• Regulatory Landscape
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Erectile Dysfunction Drugs Market by Product

• Market Overview
• Viagra (sildenafil citrate)
• Cialis (Tadalafil)
• Levitra/Staxyn (vardenafil)
• Stendra/Spedra (avanafil)
• Zydena (udenafil)
• Other Drugs

Erectile Dysfunction Drugs Market by Route of Administration

• Market Overview
• Oral Mode of Administration
• Injectable Mode of Administration
• Other Modes of Administration

Erectile Dysfunction Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hims, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sildenafil Therapeutics LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediSprout (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantKwest, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apexigen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantWorks LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tetra Bio-Pharma Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hims, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sildenafil Therapeutics LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediSprout (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantKwest, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apexigen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantWorks LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tetra Bio-Pharma Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments